TherapeuticsMD, Inc.
TXMDNext catalyst
GS1191-0445 injection
Hemophilia A
Get an email about TXMD's next catalysts
Track TherapeuticsMD (TXMD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 14 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
15 upcoming, 3 past
GS1191-0445 injection Phase 3 Est. Readout
Estimated primary completion for GS1191-0445 injection trial (NCT06833983) in Hemophilia A. Topline data typically follows completion by weeks to months.
SourceRNK08954 Phase 2 Est. Readout
Estimated primary completion for RNK08954 trial (NCT07303465) in KRAS G12D Mutations. Topline data typically follows completion by weeks to months.
SourceTH9619 Phase 2 Est. Readout
Estimated primary completion for TH9619 trial (NCT07151040) in Solid Tumor. Topline data typically follows completion by weeks to months.
SourceYL201 for Injection Phase 2 Est. Readout
Estimated primary completion for YL201 for Injection trial (NCT06241846) in Metastatic Castration-resistant Prostate Cancer (mCRPC). Topline data typically follows completion by weeks to months.
SourceALT-100 mAb Phase 2 Est. Readout
Estimated primary completion for ALT-100 mAb trial (NCT05938036) in Acute Respiratory Distress Syndrome (ARDS). Topline data typically follows completion by weeks to months.
SourceLeriglitazone Phase 3 Est. Readout
Estimated primary completion for Leriglitazone trial (NCT05819866) in Cerebral Adrenoleukodystrophy (cALD). Topline data typically follows completion by weeks to months.
SourceVeverimer Phase 3 Est. Readout
Estimated primary completion for Veverimer trial (NCT07355062) in CKD. Topline data typically follows completion by weeks to months.
SourceCT3001 Phase 2 Est. Readout
Estimated primary completion for CT3001 trial (NCT06598007) in Solid Tumor, Adult. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
ELA026
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
arbaclofen
Fragile X Syndrome
AXS-05
Agitation in Patients With Dementia of the Alzheimer's Type
Human platelets
Cardiac Surgery
DaxibotulinumtoxinA for injection
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
histrelin acetate
Prostate Cancer
Frovatriptan
Menstrually Associated Migraine
CR845
Uremic Pruritus
Plozasiran
Familial Chylomicronemia Syndrome
Oral Calcitonin Tablets
Osteoporosis, Postmenopausal
BHV-7000
Focal Epilepsy
BGF MDI
COPD
Fasedienol Nasal Spray
Social Anxiety Disorder
AC-170
Allergic Conjunctivitis
Scopolamine Nasal Gel
Motion Sickness
EN3835
Adhesive Capsulitis
pagoclone
Stuttering
AXS-05 (dextromethorphan-bupropion)
Agitation in Patients With Dementia of the Alzheimer's Type
Single-Dose IV Oritavancin Diphosphate
Wound Infection
GFF MDI (PT003)
COPD
Neridronate
Complex Regional Pain Syndrome Type I
bempedoic acid
Hypercholesterolemia
Eribulin
Locally Advanced or Metastatic Breast Cancer
ACER-002 (celiprolol)
Vascular Ehlers-Danlos Syndrome
Estradiol
Menopause
Oxymorphone Extended Release
Chronic Pain
Veverimer
CKD
Factor VIII (rFVIIIFc)
Severe Hemophilia A
DPI-386 Nasal Gel
Motion Sickness, Space
Triamcinolone Acetonide
Osteoarthritis of the Knee
Progesterone
Menopause
Xanomeline and Trospium Chloride Capsules
Schizophrenia
BFF MDI
Chronic Obstructive Pulmonary Disorder
AA4500
Peyronie's Disease
BFF MDI (PT009)
Chronic Obstructive Pulmonary Disorder
Lorecivivint
Knee Osteoarthritis
Ublituximab
Relapsing Remitting Multiple Sclerosis
FMX103 minocycline foam
Facial Papulopustular Rosacea
XIAFLEX/XIAPEX
Dupuytren's Contracture
Zelpultide alfa
Bronchopulmonary Dysplasia
oxymorphone HCl
Post Operative Pain
anamorelin HCl
Carcinoma, Non-Small-Cell Lung
GP MDI (PT001)
Chronic Obstructive Pulmonary Disease (COPD)
Dalbavancin
Abscess
Valrubicin
Carcinoma in Situ
000-0551 Lotion
Plaque Psoriasis
Topical SM04554 solution
Androgenetic Alopecia
RBT-1
Post-Operative Complications in Cardiac Surgery
Pegtibatinase
Homocystinuria
AR101 powder provided in capsules & sachets
Peanut Allergy
REL-1017
Major Depressive Disorder
A-101 Solution
Seborrheic Keratosis
Dexycu
Inflammation
Difluprednate Ophthalmic Emulsion
Inflammation
YL201
Advanced Esophageal Squamous Cell Carcinoma
Nirogacestat oral tablet
Desmoid Tumor
MST-188
Vaso-occlusive Crisis
Reproxalap Ophthalmic
Dry Eye
Moxifloxacin
Community Acquired Bacterial Pneumonia
188-0551 Spray
Plaque Psoriasis
XAF5 (concentration A:)
Steatoblepharon
PTX-022
Pachyonychia Congenita
BGF MDI (PT010)
COPD
ETC-1002
Hypercholesterolemia
BHV-1300
Graves Disease
Loncastuximab Tesirine
Relapsed Diffuse Large B-Cell Lymphoma
delafloxacin
Skin and Subcutaneous Tissue Bacterial Infections
Radiprodil
GRIN-related Neurodevelopmental Disorder
Testosterone
Hypogonadism
Nefecon
Primary IgA Nephropathy
Prednisolone Acetate
Uveitis
Botulinum Toxins, Type A
Glabellar Frown Lines
AR101
Peanut Allergy
Teriflunomide
Relapsing Multiple Sclerosis (RMS)
Triamcinolone Hexacetonide
Knee Osteoarthritis
Solriamfetol
Major Depressive Disorder
Brepocitinib PO QD
Uveitis, Posterior
Androxal
Secondary Hypogonadism
Linsitinib
Thyroid Eye Disease
ADX-102 Ophthalmic
Non-infectious Anterior Uveitis
Collagenase clostridium histolyticum
Dupuytren's Disease
enclomiphene citrate
Effect of Treatment on Bone Mineral Density
Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
COPD
Saroglitazar magnesium
Non-Alcoholic Fatty Liver Disease
FMX101
Acne Vulgaris
Tiratricol
Monocarboxylate Transporter 8 Deficiency
Meropenem-Vaborbactam
Urinary Tract Infection Complicated
AXS-07 (MoSEIC meloxicam and rizatriptan)
Migraine
KarXT
Psychosis Associated With Alzheimer's Disease
Pimicotinib(ABSK021)
Tenosynovial Giant Cell Tumor
Oral Brepocitinib
Cutaneous Sarcoidosis
cyclosporine
Dry Eye Syndromes
Leriglitazone
Cerebral Adrenoleukodystrophy (cALD)
Oxymorphone immediate release
Acute Pain
intranasal carbetocin
Prader-Willi Syndrome
Scopolamine
Motion Sickness
Difluprednate
Inflammation
YL202
Non-Small Cell Lung Cancer
JDP-205 Injection
Acute Urticaria
GS1191-0445 injection
Hemophilia A
oral estradiol
Menopause
PRO 2000/5
HIV Infections
oral progesterone
Menopause
EFB0027 (metformin delayed release)
Type 2 Diabetes Mellitus
H-1337
Glaucoma Open-Angle Primary
Usnoflast
Amyotrophic Lateral Sclerosis (ALS)
hI-con1
Choroidal Neovascularization
BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)
Colorectal Cancer
Rhu-pGSN
Acute Respiratory Distress Syndrome
MIN-102
Friedreich Ataxia
ET140203 T Cells
Hepatoblastoma
INT131 besylate
Type 2 Diabetes Mellitus
FP01
Acute Cough
TST001
Advanced Cancer
pegylated IFNa2b
Hepatitis C
Linezolid
Skin and Subcutaneous Tissue Bacterial Infections
Tranilast
Gout
GKT137831
Type 2 Diabetes Mellitus With Diabetic Nephropathy
ABT-301
Colorectal Cancer (Diagnosis)
VB10.16
HPV Positive Oropharyngeal Squamous Cell Carcinoma
AdVEGFXC1
Coronary Artery Disease
ST-100 Ophthalmic Solution
Dry Eye Disease
RT001 (Botulinum Toxin Type A Topical Gel)
Lateral Canthal Lines
JTX-8064
Cancer
NAP (Naptumomab estafenatox)
Non-small Cell Lung Cancer
Ipamorelin
Gastrointestinal Dysmotility
Testosterone undecanoate
Hypogonadism
CB-03-01
Acne Vulgaris
SOC (mTOR + CNI)
Kidney Transplantation
VK2735
Weight Loss
Latanoprost
Open-Angle Glaucoma
ECT204 T cells
Hepatocellular Carcinoma
RIST4721
Palmoplantar Pustulosis
TG-0054 combined with G-CSF
Multiple Myeloma
RNK05047
Advanced Solid Tumor
SRSD107
Coronary Artery Disease (CAD)
PER-001 Intravitreal Implant - Low Dose
Diabetic Retinopathy
Proellex
Uterine Fibroids
RNK08954
KRAS G12D Mutations
DAXXIFY
Glabellar Frown Lines
JCARH125
Multiple Myeloma
pTTL
Colorectal Cancer
SM04554
Androgenetic Alopecia
AT-007
Classic Galactosemia
TT-034
Hepatitis C
EHT102 Injection
Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Radezolid
Community-Acquired Pneumonia (CAP)
RZL-012+Lidacaine injection prior treatment
Submental Fat
ACER-801
Post-menopausal Vasomotor Symptoms
Bone marrow mesenchymal stem cells
Osteoarthritis, Knee
TH9619
Solid Tumor
ABT-101
Advanced Solid Tumor
RNK08954-01
KRAS G12D Mutation
ST-01
Chronic Pain
Cenicriviroc
HIV-1 Infection
Telapristone Acetate
Uterine Fibroids
BIO-106
Advanced Cancer
Latanoprost Punctal Plug Delivery System
Ocular Hypertension
Lidoderm
Osteoarthritis, Knee
Glycopyrronium MDI
Asthma
AVZO-1418
Solid Tumor Cancer
Aglatimagene besadenovec
Borderline Resectable Pancreatic Adenocarcinoma
EL219
Invasive Mould Infection
AMT-116
Advanced Solid Tumors
AC-150 Combo
Allergic Conjunctivitis
TNP-2092 capsules
Hyperammonemia
Camidanlumab Tesirine
Relapsed Hodgkin Lymphoma
Met DR
Type 2 Diabetes Mellitus
Active
Asthma
PRTX007
Melanoma Stage III
AXS-12 (Reboxetine)
Narcolepsy
PTX-200
Acute Leukemia
Oral rsCT tablet
Phase 1 Pharmacodynamic Study
AFNT-211
Pancreatic Ductal Adenocarcinoma
RM-131
Constipation
Triac
Allan-Herndon-Dudley Syndrome
CTI-1601
Friedreich Ataxia
Inhaled PT001
Chronic Obstructive Pulmonary Disease
ABSK061 + ABSK043
HER2-Gastric/Gastroesophageal Junction Cancer
AVZO-021
Advanced Solid Tumor
QTORIN rapamycin anhydrous
Cutaneous Venous Malformations
ABSK-011+BSC
Hepatocellular Carcinoma (HCC)
NVG-2089
Immune Thrombocytopenia (ITP)
NPT 2042
Epilepsy, Generalized
MGCD0103
Lymphoma
FT-2102
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)
MAA868 Cohort 1
Atrial Fibrillation
Nexagon® Low Dose
Venous Leg Ulcers
BC-819/PEI
Superficial Bladder Cancer
VLS-1488
Advanced Solid Tumor
NDV-3A
Vulvovaginal Candidiasis
octreotide acetate
Acromegaly
RAP-219
Focal Epilepsy
VDA-1102
Actinic Keratosis
UHE-101 Cream
Acne Vulgaris
Faldaprevir
Hepatitis C Viral Infection
ATI-450
Hidradenitis Suppurativa
PTG-300
Polycythemia Vera
TDM-105795
Alopecia, Androgenetic
MSDC-0602K
Non-alcoholic Fatty Liver Disease
Allo-QuadCAR01-T
Lymphoma Diffuse Large B-cell
188-0551 Solution
Plaque Psoriasis
IG3018
Hyperuricemia
YL201 for Injection
Advanced Solid Tumor
Serlopitant
Pruritus
Halobetasol Propionate Lotion
Psoriasis
OPN-305
Myelodysplastic Syndrome
Gene Therapy product:vMCO-I
Retinitis Pigmentosa
GFH018
NSCLC, Stage III
Sevuparin
Sickle-Cell Disease
voretigene neparvovec-rzyl
Leber Congenital Amaurosis
SRP1020
Advanced Solid Tumors
Gene Therapy Product-MCO-010
Retinitis Pigmentosa
Oral Testosterone Undecanoate
Hypogonadism
UHE-105
Scalp Psoriasis
Recombinant Human Plasma Gelsolin
Community-acquired Pneumonia
NT100
Repeated IVF Failure
XOPH5 Ointment
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
fludarabine phosphate
Accelerated Phase Chronic Myelogenous Leukemia
ABSK043 in combination with Glecirasib
Non-Small Cell Lung Cancer
PT-112
Non-Small Cell Lung Cancer (NSCLC)
ABSK043 in combination with Firmonertinib
Non-Small Cell Lung Cancer With EGFR Mutation
trospium chloride inhalation powder (TrIP)
Chronic Obstructive Pulmonary Disease
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
Adult Brain Glioblastoma
Brepocitinib
Dermatomyositis
DAXI
Plantar Fasciitis
Norketotifen
Allergic Rhinitis
LT3001 Drug Product
Acute Ischemic Stroke
ABX-002
Major Depressive Disorder
ETX-018810
Diabetic Peripheral Neuropathic Pain
ALT-100 mAb
Acute Respiratory Distress Syndrome (ARDS)
CT-868
Obesity
RT001 Botulinum toxin type A (Dose A)
Lateral Canthal Lines
AHB-137
Hepatitis B, Chronic
ANG003 Dose A
Exocrine Pancreatic Insufficiency (EPI)
SF0166 Topical Ophthalmic Solution
Age-Related Macular Degeneration
Eteplirsen
Muscular Dystrophy, Duchenne
Etavopivat
Sickle Cell Disease
ADX-629
Chronic Cough
BTRX-246040
Parkinson Disease
IMC-001
Extranodal NK/T-cell Lymphoma, Nasal Type
Enicepatide
Obesity
ARD-101
Bariatric Surgery
CCH-aaes
Edematous Fibrosclerotic Panniculopathy
SM04690
Osteoarthritis
VSA006
Nash
HG004
Leber Congenital Amaurosis
Tagraxofusp
Acute Myeloid Leukemia
Bemarituzumab
Gastric Cancer
AZD2115 Dose 1
Chronic Obstructive Pulmonary Disease (COPD)
INT-210 Capsule
Ulcerative Colitis (UC)
SKP-1041 (experimental formulation of zaleplon)
Sleep Disorder
CT3001
Solid Tumor, Adult
CT041
Gastric Cancer
Saroglitazar
Liver Transplant; Complications
JPI-547
Pancreatic Ductal Adenocarcinoma
Solabegron immediate release tablets, low dose
Overactive Bladder
Varenicline tartrate
Trigeminal Neuralgia
RZL-012
Submental Fat
T3D-959
Alzheimer Disease
Solabegron modified release tablets, low dose
Overactive Bladder
RT001
Lateral Canthal Lines
Trivalent ganglioside vaccine
Sarcoma
PT005 MDI
Chronic Obstructive Pulmonary Disease
PTI-808
Healthy Volunteer - Complete
Oral testosterone undecanoate (containing T)
Male Hypogonadism
TD-6450
Hepatitis C Viral Infection
VAL-083, Dianhydrogalactitol
Glioma
Mocetinostat
Urothelial Carcinoma
YL202 should be intravenously infused
NSCLC
NFX-179 gel
Cutaneous Neurofibroma
LM103 TILs Injection
Non-Small Cell Lung Cancer
PT001 MDI
Chronic Obstructive Pulmonary Disease
YL242
Advanced Solid Tumor
dotinurad
Gout
Orvepitant Maleate
Chronic Refractory Cough
botulinum toxin, Type A
Lateral Canthal Lines
CQSS2
Smoking Cessation
ETX-19477
Advanced or Metastatic Solid Tumors
Latanoprost-PPDS
Glaucoma
2B3-101
Brain Metastases
TG-0054
Multiple Myeloma
FT-2102 (olutasidenib)
Acute Myeloid Leukemia
CTS3497
Solid Tumor
Gene Therapy-vMCO-010
Stargardt Disease
A-101
Seborrheic Keratosis
Naproxen sodium
Gastric Ulcer
LY2940094
Alcoholism
lisocabtagene maraleucel
Lymphoma, Non-Hodgkin
TNP-2092 for injection
Periprosthetic Joint Infection (PJI)
AVZO-103
Solid Tumor Cancer
NMRA-335140
Major Depressive Disorder
JP-1366
GERD
T0903131 Besylate
Diabetes Mellitus, Type II
hPSC-CM Therapy
Heart Failure
SLS-002
Depressive Disorder, Major
Botulinum Toxin Type A
Glabellar Frown Lines
Setanaxib
Alport Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ELA026 | Phase 3 | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | - | - |
arbaclofen | Phase 3 | Fragile X Syndrome | - | - |
AXS-05 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type | - | - |
Human platelets | Phase 3 | Cardiac Surgery | - | - |
DaxibotulinumtoxinA for injection | Phase 3 | Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) | - | - |
histrelin acetate | Phase 3 | Prostate Cancer | - | - |
Frovatriptan | Phase 3 | Menstrually Associated Migraine | - | - |
CR845 | Phase 3 | Uremic Pruritus | - | - |
Plozasiran | Phase 3 | Familial Chylomicronemia Syndrome | - | - |
Oral Calcitonin Tablets | Phase 3 | Osteoporosis, Postmenopausal | - | - |
BHV-7000 | Phase 3 | Focal Epilepsy | - | - |
BGF MDI | Phase 3 | COPD | - | - |
Fasedienol Nasal Spray | Phase 3 | Social Anxiety Disorder | - | - |
AC-170 | Phase 3 | Allergic Conjunctivitis | - | - |
Scopolamine Nasal Gel | Phase 3 | Motion Sickness | - | - |
EN3835 | Phase 3 | Adhesive Capsulitis | - | - |
pagoclone | Phase 3 | Stuttering | - | - |
AXS-05 (dextromethorphan-bupropion) | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type | - | - |
Single-Dose IV Oritavancin Diphosphate | Phase 3 | Wound Infection | - | - |
GFF MDI (PT003) | Phase 3 | COPD | - | - |
Neridronate | Phase 3 | Complex Regional Pain Syndrome Type I | - | - |
bempedoic acid | Phase 3 | Hypercholesterolemia | - | - |
Eribulin | Phase 3 | Locally Advanced or Metastatic Breast Cancer | - | - |
ACER-002 (celiprolol) | Phase 3 | Vascular Ehlers-Danlos Syndrome | - | - |
Estradiol | Phase 3 | Menopause | - | - |
Oxymorphone Extended Release | Phase 3 | Chronic Pain | - | - |
Veverimer | Phase 3 | CKD | - | - |
Factor VIII (rFVIIIFc) | Phase 3 | Severe Hemophilia A | - | - |
DPI-386 Nasal Gel | Phase 3 | Motion Sickness, Space | - | - |
Triamcinolone Acetonide | Phase 3 | Osteoarthritis of the Knee | - | - |
Progesterone | Phase 3 | Menopause | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
BFF MDI | Phase 3 | Chronic Obstructive Pulmonary Disorder | - | - |
AA4500 | Phase 3 | Peyronie's Disease | - | - |
BFF MDI (PT009) | Phase 3 | Chronic Obstructive Pulmonary Disorder | - | - |
Lorecivivint | Phase 3 | Knee Osteoarthritis | - | - |
Ublituximab | Phase 3 | Relapsing Remitting Multiple Sclerosis | - | - |
FMX103 minocycline foam | Phase 3 | Facial Papulopustular Rosacea | - | - |
XIAFLEX/XIAPEX | Phase 3 | Dupuytren's Contracture | - | - |
Zelpultide alfa | Phase 3 | Bronchopulmonary Dysplasia | - | - |
oxymorphone HCl | Phase 3 | Post Operative Pain | - | - |
anamorelin HCl | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
GP MDI (PT001) | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Dalbavancin | Phase 3 | Abscess | - | - |
Valrubicin | Phase 3 | Carcinoma in Situ | - | - |
000-0551 Lotion | Phase 3 | Plaque Psoriasis | - | - |
Topical SM04554 solution | Phase 3 | Androgenetic Alopecia | - | - |
RBT-1 | Phase 3 | Post-Operative Complications in Cardiac Surgery | - | - |
Pegtibatinase | Phase 3 | Homocystinuria | - | - |
AR101 powder provided in capsules & sachets | Phase 3 | Peanut Allergy | - | - |
REL-1017 | Phase 3 | Major Depressive Disorder | - | - |
A-101 Solution | Phase 3 | Seborrheic Keratosis | - | - |
Dexycu | Phase 3 | Inflammation | - | - |
Difluprednate Ophthalmic Emulsion | Phase 3 | Inflammation | - | - |
YL201 | Phase 3 | Advanced Esophageal Squamous Cell Carcinoma | - | - |
Nirogacestat oral tablet | Phase 3 | Desmoid Tumor | - | - |
MST-188 | Phase 3 | Vaso-occlusive Crisis | - | - |
Reproxalap Ophthalmic | Phase 3 | Dry Eye | - | - |
Moxifloxacin | Phase 3 | Community Acquired Bacterial Pneumonia | - | - |
188-0551 Spray | Phase 3 | Plaque Psoriasis | - | - |
XAF5 (concentration A:) | Phase 3 | Steatoblepharon | - | - |
PTX-022 | Phase 3 | Pachyonychia Congenita | - | - |
BGF MDI (PT010) | Phase 3 | COPD | - | - |
ETC-1002 | Phase 3 | Hypercholesterolemia | - | - |
BHV-1300 | Phase 3 | Graves Disease | - | - |
Loncastuximab Tesirine | Phase 3 | Relapsed Diffuse Large B-Cell Lymphoma | - | - |
delafloxacin | Phase 3 | Skin and Subcutaneous Tissue Bacterial Infections | - | - |
Radiprodil | Phase 3 | GRIN-related Neurodevelopmental Disorder | - | - |
Testosterone | Phase 3 | Hypogonadism | - | - |
Nefecon | Phase 3 | Primary IgA Nephropathy | - | - |
Prednisolone Acetate | Phase 3 | Uveitis | - | - |
Botulinum Toxins, Type A | Phase 3 | Glabellar Frown Lines | - | - |
AR101 | Phase 3 | Peanut Allergy | - | - |
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis (RMS) | - | - |
Triamcinolone Hexacetonide | Phase 3 | Knee Osteoarthritis | - | - |
Solriamfetol | Phase 3 | Major Depressive Disorder | - | - |
Brepocitinib PO QD | Phase 3 | Uveitis, Posterior | - | - |
Androxal | Phase 3 | Secondary Hypogonadism | - | - |
Linsitinib | Phase 3 | Thyroid Eye Disease | - | - |
ADX-102 Ophthalmic | Phase 3 | Non-infectious Anterior Uveitis | - | - |
Collagenase clostridium histolyticum | Phase 3 | Dupuytren's Disease | - | - |
enclomiphene citrate | Phase 3 | Effect of Treatment on Bone Mineral Density | - | - |
Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler | Phase 3 | COPD | - | - |
Saroglitazar magnesium | Phase 3 | Non-Alcoholic Fatty Liver Disease | - | - |
FMX101 | Phase 3 | Acne Vulgaris | - | - |
Tiratricol | Phase 3 | Monocarboxylate Transporter 8 Deficiency | - | - |
Meropenem-Vaborbactam | Phase 3 | Urinary Tract Infection Complicated | - | - |
AXS-07 (MoSEIC meloxicam and rizatriptan) | Phase 3 | Migraine | - | - |
KarXT | Phase 3 | Psychosis Associated With Alzheimer's Disease | - | - |
Pimicotinib(ABSK021) | Phase 3 | Tenosynovial Giant Cell Tumor | - | - |
Oral Brepocitinib | Phase 3 | Cutaneous Sarcoidosis | - | - |
cyclosporine | Phase 3 | Dry Eye Syndromes | - | - |
Leriglitazone | Phase 3 | Cerebral Adrenoleukodystrophy (cALD) | - | - |
Oxymorphone immediate release | Phase 3 | Acute Pain | - | - |
intranasal carbetocin | Phase 3 | Prader-Willi Syndrome | - | - |
Scopolamine | Phase 3 | Motion Sickness | - | - |
Difluprednate | Phase 3 | Inflammation | - | - |
YL202 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
JDP-205 Injection | Phase 3 | Acute Urticaria | - | - |
GS1191-0445 injection | Phase 3 | Hemophilia A | - | - |
oral estradiol | Phase 3 | Menopause | - | - |
PRO 2000/5 | Phase 3 | HIV Infections | - | - |
oral progesterone | Phase 3 | Menopause | - | - |
EFB0027 (metformin delayed release) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
H-1337 | Phase 2 | Glaucoma Open-Angle Primary | - | - |
Usnoflast | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
hI-con1 | Phase 2 | Choroidal Neovascularization | - | - |
BOLD-100 +/- FOLFOX Chemotherapy (Arm VII) | Phase 2 | Colorectal Cancer | - | - |
Rhu-pGSN | Phase 2 | Acute Respiratory Distress Syndrome | - | - |
MIN-102 | Phase 2 | Friedreich Ataxia | - | - |
ET140203 T Cells | Phase 2 | Hepatoblastoma | - | - |
INT131 besylate | Phase 2 | Type 2 Diabetes Mellitus | - | - |
FP01 | Phase 2 | Acute Cough | - | - |
TST001 | Phase 2 | Advanced Cancer | - | - |
pegylated IFNa2b | Phase 2 | Hepatitis C | - | - |
Linezolid | Phase 2 | Skin and Subcutaneous Tissue Bacterial Infections | - | - |
Tranilast | Phase 2 | Gout | - | - |
GKT137831 | Phase 2 | Type 2 Diabetes Mellitus With Diabetic Nephropathy | - | - |
ABT-301 | Phase 2 | Colorectal Cancer (Diagnosis) | - | - |
VB10.16 | Phase 2 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | - | - |
AdVEGFXC1 | Phase 2 | Coronary Artery Disease | - | - |
ST-100 Ophthalmic Solution | Phase 2 | Dry Eye Disease | - | - |
RT001 (Botulinum Toxin Type A Topical Gel) | Phase 2 | Lateral Canthal Lines | - | - |
JTX-8064 | Phase 2 | Cancer | - | - |
NAP (Naptumomab estafenatox) | Phase 2 | Non-small Cell Lung Cancer | - | - |
Ipamorelin | Phase 2 | Gastrointestinal Dysmotility | - | - |
Testosterone undecanoate | Phase 2 | Hypogonadism | - | - |
CB-03-01 | Phase 2 | Acne Vulgaris | - | - |
SOC (mTOR + CNI) | Phase 2 | Kidney Transplantation | - | - |
VK2735 | Phase 2 | Weight Loss | - | - |
Latanoprost | Phase 2 | Open-Angle Glaucoma | - | - |
ECT204 T cells | Phase 2 | Hepatocellular Carcinoma | - | - |
RIST4721 | Phase 2 | Palmoplantar Pustulosis | - | - |
TG-0054 combined with G-CSF | Phase 2 | Multiple Myeloma | - | - |
RNK05047 | Phase 2 | Advanced Solid Tumor | - | - |
SRSD107 | Phase 2 | Coronary Artery Disease (CAD) | - | - |
PER-001 Intravitreal Implant - Low Dose | Phase 2 | Diabetic Retinopathy | - | - |
Proellex | Phase 2 | Uterine Fibroids | - | - |
RNK08954 | Phase 2 | KRAS G12D Mutations | - | - |
DAXXIFY | Phase 2 | Glabellar Frown Lines | - | - |
JCARH125 | Phase 2 | Multiple Myeloma | - | - |
pTTL | Phase 2 | Colorectal Cancer | - | - |
SM04554 | Phase 2 | Androgenetic Alopecia | - | - |
AT-007 | Phase 2 | Classic Galactosemia | - | - |
TT-034 | Phase 2 | Hepatitis C | - | - |
EHT102 Injection | Phase 2 | Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | - | - |
Radezolid | Phase 2 | Community-Acquired Pneumonia (CAP) | - | - |
RZL-012+Lidacaine injection prior treatment | Phase 2 | Submental Fat | - | - |
ACER-801 | Phase 2 | Post-menopausal Vasomotor Symptoms | - | - |
Bone marrow mesenchymal stem cells | Phase 2 | Osteoarthritis, Knee | - | - |
TH9619 | Phase 2 | Solid Tumor | - | - |
ABT-101 | Phase 2 | Advanced Solid Tumor | - | - |
RNK08954-01 | Phase 2 | KRAS G12D Mutation | - | - |
ST-01 | Phase 2 | Chronic Pain | - | - |
Cenicriviroc | Phase 2 | HIV-1 Infection | - | - |
Telapristone Acetate | Phase 2 | Uterine Fibroids | - | - |
BIO-106 | Phase 2 | Advanced Cancer | - | - |
Latanoprost Punctal Plug Delivery System | Phase 2 | Ocular Hypertension | - | - |
Lidoderm | Phase 2 | Osteoarthritis, Knee | - | - |
Glycopyrronium MDI | Phase 2 | Asthma | - | - |
AVZO-1418 | Phase 2 | Solid Tumor Cancer | - | - |
Aglatimagene besadenovec | Phase 2 | Borderline Resectable Pancreatic Adenocarcinoma | - | - |
EL219 | Phase 2 | Invasive Mould Infection | - | - |
AMT-116 | Phase 2 | Advanced Solid Tumors | - | - |
AC-150 Combo | Phase 2 | Allergic Conjunctivitis | - | - |
TNP-2092 capsules | Phase 2 | Hyperammonemia | - | - |
Camidanlumab Tesirine | Phase 2 | Relapsed Hodgkin Lymphoma | - | - |
Met DR | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Active | Phase 2 | Asthma | - | - |
PRTX007 | Phase 2 | Melanoma Stage III | - | - |
AXS-12 (Reboxetine) | Phase 2 | Narcolepsy | - | - |
PTX-200 | Phase 2 | Acute Leukemia | - | - |
Oral rsCT tablet | Phase 2 | Phase 1 Pharmacodynamic Study | - | - |
AFNT-211 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
RM-131 | Phase 2 | Constipation | - | - |
Triac | Phase 2 | Allan-Herndon-Dudley Syndrome | - | - |
CTI-1601 | Phase 2 | Friedreich Ataxia | - | - |
Inhaled PT001 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
ABSK061 + ABSK043 | Phase 2 | HER2-Gastric/Gastroesophageal Junction Cancer | - | - |
AVZO-021 | Phase 2 | Advanced Solid Tumor | - | - |
QTORIN rapamycin anhydrous | Phase 2 | Cutaneous Venous Malformations | - | - |
ABSK-011+BSC | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
NVG-2089 | Phase 2 | Immune Thrombocytopenia (ITP) | - | - |
NPT 2042 | Phase 2 | Epilepsy, Generalized | - | - |
MGCD0103 | Phase 2 | Lymphoma | - | - |
FT-2102 | Phase 2 | Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) | - | - |
MAA868 Cohort 1 | Phase 2 | Atrial Fibrillation | - | - |
Nexagon® Low Dose | Phase 2 | Venous Leg Ulcers | - | - |
BC-819/PEI | Phase 2 | Superficial Bladder Cancer | - | - |
VLS-1488 | Phase 2 | Advanced Solid Tumor | - | - |
NDV-3A | Phase 2 | Vulvovaginal Candidiasis | - | - |
octreotide acetate | Phase 2 | Acromegaly | - | - |
RAP-219 | Phase 2 | Focal Epilepsy | - | - |
VDA-1102 | Phase 2 | Actinic Keratosis | - | - |
UHE-101 Cream | Phase 2 | Acne Vulgaris | - | - |
Faldaprevir | Phase 2 | Hepatitis C Viral Infection | - | - |
ATI-450 | Phase 2 | Hidradenitis Suppurativa | - | - |
PTG-300 | Phase 2 | Polycythemia Vera | - | - |
TDM-105795 | Phase 2 | Alopecia, Androgenetic | - | - |
MSDC-0602K | Phase 2 | Non-alcoholic Fatty Liver Disease | - | - |
Allo-QuadCAR01-T | Phase 2 | Lymphoma Diffuse Large B-cell | - | - |
188-0551 Solution | Phase 2 | Plaque Psoriasis | - | - |
IG3018 | Phase 2 | Hyperuricemia | - | - |
YL201 for Injection | Phase 2 | Advanced Solid Tumor | - | - |
Serlopitant | Phase 2 | Pruritus | - | - |
Halobetasol Propionate Lotion | Phase 2 | Psoriasis | - | - |
OPN-305 | Phase 2 | Myelodysplastic Syndrome | - | - |
Gene Therapy product:vMCO-I | Phase 2 | Retinitis Pigmentosa | - | - |
GFH018 | Phase 2 | NSCLC, Stage III | - | - |
Sevuparin | Phase 2 | Sickle-Cell Disease | - | - |
voretigene neparvovec-rzyl | Phase 2 | Leber Congenital Amaurosis | - | - |
SRP1020 | Phase 2 | Advanced Solid Tumors | - | - |
Gene Therapy Product-MCO-010 | Phase 2 | Retinitis Pigmentosa | - | - |
Oral Testosterone Undecanoate | Phase 2 | Hypogonadism | - | - |
UHE-105 | Phase 2 | Scalp Psoriasis | - | - |
Recombinant Human Plasma Gelsolin | Phase 2 | Community-acquired Pneumonia | - | - |
NT100 | Phase 2 | Repeated IVF Failure | - | - |
XOPH5 Ointment | Phase 2 | Lower Eyelid Steatoblepharon (Excess Eyelid Fat) | - | - |
fludarabine phosphate | Phase 2 | Accelerated Phase Chronic Myelogenous Leukemia | - | - |
ABSK043 in combination with Glecirasib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
PT-112 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
ABSK043 in combination with Firmonertinib | Phase 2 | Non-Small Cell Lung Cancer With EGFR Mutation | - | - |
trospium chloride inhalation powder (TrIP) | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose) | Phase 2 | Adult Brain Glioblastoma | - | - |
Brepocitinib | Phase 2 | Dermatomyositis | - | - |
DAXI | Phase 2 | Plantar Fasciitis | - | - |
Norketotifen | Phase 2 | Allergic Rhinitis | - | - |
LT3001 Drug Product | Phase 2 | Acute Ischemic Stroke | - | - |
ABX-002 | Phase 2 | Major Depressive Disorder | - | - |
ETX-018810 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
ALT-100 mAb | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | - | - |
CT-868 | Phase 2 | Obesity | - | - |
RT001 Botulinum toxin type A (Dose A) | Phase 2 | Lateral Canthal Lines | - | - |
AHB-137 | Phase 2 | Hepatitis B, Chronic | - | - |
ANG003 Dose A | Phase 2 | Exocrine Pancreatic Insufficiency (EPI) | - | - |
SF0166 Topical Ophthalmic Solution | Phase 2 | Age-Related Macular Degeneration | - | - |
Eteplirsen | Phase 2 | Muscular Dystrophy, Duchenne | - | - |
Etavopivat | Phase 2 | Sickle Cell Disease | - | - |
ADX-629 | Phase 2 | Chronic Cough | - | - |
BTRX-246040 | Phase 2 | Parkinson Disease | - | - |
IMC-001 | Phase 2 | Extranodal NK/T-cell Lymphoma, Nasal Type | - | - |
Enicepatide | Phase 2 | Obesity | - | - |
ARD-101 | Phase 2 | Bariatric Surgery | - | - |
CCH-aaes | Phase 2 | Edematous Fibrosclerotic Panniculopathy | - | - |
SM04690 | Phase 2 | Osteoarthritis | - | - |
VSA006 | Phase 2 | Nash | - | - |
HG004 | Phase 2 | Leber Congenital Amaurosis | - | - |
Tagraxofusp | Phase 2 | Acute Myeloid Leukemia | - | - |
Bemarituzumab | Phase 2 | Gastric Cancer | - | - |
AZD2115 Dose 1 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
INT-210 Capsule | Phase 2 | Ulcerative Colitis (UC) | - | - |
SKP-1041 (experimental formulation of zaleplon) | Phase 2 | Sleep Disorder | - | - |
CT3001 | Phase 2 | Solid Tumor, Adult | - | - |
CT041 | Phase 2 | Gastric Cancer | - | - |
Saroglitazar | Phase 2 | Liver Transplant; Complications | - | - |
JPI-547 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
Solabegron immediate release tablets, low dose | Phase 2 | Overactive Bladder | - | - |
Varenicline tartrate | Phase 2 | Trigeminal Neuralgia | - | - |
RZL-012 | Phase 2 | Submental Fat | - | - |
T3D-959 | Phase 2 | Alzheimer Disease | - | - |
Solabegron modified release tablets, low dose | Phase 2 | Overactive Bladder | - | - |
RT001 | Phase 2 | Lateral Canthal Lines | - | - |
Trivalent ganglioside vaccine | Phase 2 | Sarcoma | - | - |
PT005 MDI | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
PTI-808 | Phase 2 | Healthy Volunteer - Complete | - | - |
Oral testosterone undecanoate (containing T) | Phase 2 | Male Hypogonadism | - | - |
TD-6450 | Phase 2 | Hepatitis C Viral Infection | - | - |
VAL-083, Dianhydrogalactitol | Phase 2 | Glioma | - | - |
Mocetinostat | Phase 2 | Urothelial Carcinoma | - | - |
YL202 should be intravenously infused | Phase 2 | NSCLC | - | - |
NFX-179 gel | Phase 2 | Cutaneous Neurofibroma | - | - |
LM103 TILs Injection | Phase 2 | Non-Small Cell Lung Cancer | - | - |
PT001 MDI | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
YL242 | Phase 2 | Advanced Solid Tumor | - | - |
dotinurad | Phase 2 | Gout | - | - |
Orvepitant Maleate | Phase 2 | Chronic Refractory Cough | - | - |
botulinum toxin, Type A | Phase 2 | Lateral Canthal Lines | - | - |
CQSS2 | Phase 2 | Smoking Cessation | - | - |
ETX-19477 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Latanoprost-PPDS | Phase 2 | Glaucoma | - | - |
2B3-101 | Phase 2 | Brain Metastases | - | - |
TG-0054 | Phase 2 | Multiple Myeloma | - | - |
FT-2102 (olutasidenib) | Phase 2 | Acute Myeloid Leukemia | - | - |
CTS3497 | Phase 2 | Solid Tumor | - | - |
Gene Therapy-vMCO-010 | Phase 2 | Stargardt Disease | - | - |
A-101 | Phase 2 | Seborrheic Keratosis | - | - |
Naproxen sodium | Phase 2 | Gastric Ulcer | - | - |
LY2940094 | Phase 2 | Alcoholism | - | - |
lisocabtagene maraleucel | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
TNP-2092 for injection | Phase 2 | Periprosthetic Joint Infection (PJI) | - | - |
AVZO-103 | Phase 2 | Solid Tumor Cancer | - | - |
NMRA-335140 | Phase 2 | Major Depressive Disorder | - | - |
JP-1366 | Phase 2 | GERD | - | - |
T0903131 Besylate | Phase 2 | Diabetes Mellitus, Type II | - | - |
hPSC-CM Therapy | Phase 2 | Heart Failure | - | - |
SLS-002 | Phase 2 | Depressive Disorder, Major | - | - |
Botulinum Toxin Type A | Phase 2 | Glabellar Frown Lines | - | - |
Setanaxib | Phase 2 | Alport Syndrome | - | - |
Major Depressive Disorder
1 drug in this indication
Polycythemia Vera
1 drug in this indication
Effect of Treatment on Bone Mineral Density
1 drug in this indication
Hidradenitis Suppurativa
1 drug in this indication
Psychosis Associated With Alzheimer's Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in TherapeuticsMD, Inc.'s drug pipeline?→
CatalystAlert tracks 298 drug candidates in TherapeuticsMD, Inc.'s (TXMD) pipeline across Phase 3, Phase 2. Its lead program is GS1191-0445 injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TherapeuticsMD, Inc.'s next FDA catalyst?→
TherapeuticsMD, Inc.'s (TXMD) next tracked catalyst is a Phase 3 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TXMD biotech catalysts?→
Add TXMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TherapeuticsMD, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
